# Clover Health Investments, Corp.: overview

CLOV · Nasdaq · CIK 1801170 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clov.md) · [Financials](/companies/clov/financials.md) · [Filings](/companies/clov/filings.md) · [Insiders](/companies/clov/insiders.md)

Latest reported revenue: [$743.2m](/filings/0001801170-26-000200.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:Revenues, accession 0001801170-26-000200).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [331](/filings/0001801170-25-000275.md) | [337 d](/filings/0001801170-26-000057.md) | [462](/filings/0001801170-26-000122.md) | [478](/filings/0001801170-26-000200.md) | [497](/filings/0001801170-25-000275.md) | [488 d](/filings/0001801170-26-000057.md) | [749](/filings/0001801170-26-000122.md) | [743](/filings/0001801170-26-000200.md) |
| Gross margin | % | [24.5%](/filings/0001801170-24-000234.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(2.7%)](/filings/0001801170-25-000275.md) | [(6.4%) d](/filings/0001801170-26-000057.md) | [(0.3%)](/filings/0001801170-26-000122.md) | [(2.2%)](/filings/0001801170-26-000200.md) | [(4.9%)](/filings/0001801170-25-000275.md) | [(10.1%) d](/filings/0001801170-26-000057.md) | [3.6%](/filings/0001801170-26-000122.md) | [3.8%](/filings/0001801170-26-000200.md) |
| Net margin | % | [(2.8%)](/filings/0001801170-25-000275.md) | [(6.6%) d](/filings/0001801170-26-000057.md) | [(0.3%)](/filings/0001801170-26-000200.md) | [(2.2%)](/filings/0001801170-26-000200.md) | [(4.9%)](/filings/0001801170-25-000275.md) | [(10.1%) d](/filings/0001801170-26-000057.md) | [3.6%](/filings/0001801170-26-000200.md) | [3.8%](/filings/0001801170-26-000200.md) |
| Diluted EPS | $ per share | not reported | not reported | [0.00](/filings/0001801170-26-000122.md) | [(0.02)](/filings/0001801170-26-000200.md) | not reported | not reported | [0.05](/filings/0001801170-26-000122.md) | [0.05](/filings/0001801170-26-000200.md) |
| Free cash flow | $m | [49.6 d](/filings/0001801170-25-000275.md) | [(86.1) d](/filings/0001801170-26-000057.md) | [(16.5)](/filings/0001801170-26-000122.md) | [4.8 d](/filings/0001801170-26-000200.md) | [11.4 d](/filings/0001801170-25-000275.md) | [(68.7) d](/filings/0001801170-26-000057.md) | [107](/filings/0001801170-26-000122.md) | [24.5 d](/filings/0001801170-26-000200.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,472](/filings/0001801170-24-000064.md) | [1,097](/filings/0001801170-25-000052.md) | [1,261](/filings/0001801170-26-000057.md) | [1,371](/filings/0001801170-26-000057.md) | [1,924](/filings/0001801170-26-000057.md) |
| Gross margin | % | [(5.4%)](/filings/0001801170-23-000015.md) | [6.4%](/filings/0001801170-24-000234.md) | [20.4%](/filings/0001801170-24-000064.md) | not reported | not reported |
| Operating margin | % | [(43.3%)](/filings/0001801170-24-000064.md) | [(26.1%)](/filings/0001801170-25-000052.md) | [(16.3%)](/filings/0001801170-26-000057.md) | [(3.3%)](/filings/0001801170-26-000057.md) | [(4.4%)](/filings/0001801170-26-000057.md) |
| Net margin | % | [(39.9%)](/filings/0001801170-24-000064.md) | [(31.0%)](/filings/0001801170-25-000052.md) | [(16.9%)](/filings/0001801170-26-000057.md) | [(3.1%)](/filings/0001801170-26-000057.md) | [(4.4%)](/filings/0001801170-26-000057.md) |
| Diluted EPS | $ per share | [(1.42)](/filings/0001801170-24-000064.md) | [(0.71)](/filings/0001801170-24-000064.md) | [(0.44)](/filings/0001801170-24-000064.md) | not reported | not reported |
| Free cash flow | $m | [(283)](/filings/0001801170-24-000064.md) | [(208)](/filings/0001801170-25-000052.md) | [(145)](/filings/0001801170-26-000057.md) | [33.3](/filings/0001801170-26-000057.md) | [(69.0)](/filings/0001801170-26-000057.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/clov/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $184.0m | 35,106,965 |  | Added +3,266,453 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $94.5m | 18,037,661 |  | Added +1,055,588 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $56.8m | 10,846,066 |  | Added +790,556 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $53.3m | 10,180,337 |  | Added +620,448 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $37.8m | 7,205,400 | Call | Added +4,285,900 |
| [Nuveen, LLC](/funds/1871926.md) | 2026-06-30 | $33.0m | 6,291,699 |  | Added +5,356,156 |
| [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $28.9m | 5,521,188 |  | Added +220,713 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $23.4m | 4,470,452 |  | Added +774,015 |
| [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $19.8m | 3,772,600 |  | Added +466,025 |
| [PNC Financial Services Group, Inc.](/funds/713676.md) | 2026-06-30 | $18.7m | 3,563,874 |  | Reduced −200,160 |

## Recent filings

[All 706 filings](/companies/clov/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 23:13 ET | [8-K](/filings/0001801170-26-000250.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001801170-26-000250 |
| 2026-09-25 | 21:41 ET | [8-K/A](/filings/0001801170-26-000232.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001801170-26-000232 |
| 2026-09-24 | 20:31 ET | [8-K](/filings/0001801170-26-000229.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001801170-26-000229 |
| 2026-08-20 | 20:06 ET | [8-K](/filings/0001801170-26-000214.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001801170-26-000214 |
| 2026-08-07 | 12:04 ET | [10-Q](/filings/0001801170-26-000200.md) | Quarterly report, period 2026-06-30 | 0001801170-26-000200 |
| 2026-08-05 | 20:07 ET | [8-K](/filings/0001801170-26-000196.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001801170-26-000196 |
| 2026-07-17 | 20:05 ET | [8-K](/filings/0001801170-26-000181.md) | 8.01 Other events | 0001801170-26-000181 |
| 2026-06-18 | 20:05 ET | [8-K](/filings/0001801170-26-000166.md) | 8.01 Other events | 0001801170-26-000166 |
| 2026-06-16 | 20:05 ET | [8-K](/filings/0001801170-26-000153.md) | 5.02 Departure or appointment of officers or directors | 0001801170-26-000153 |
| 2026-06-12 | 20:05 ET | [8-K](/filings/0001801170-26-000148.md) | 5.07 Shareholder vote results | 0001801170-26-000148 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001801170-26-000057.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/cdea82b1-6e55-4c72-9862-dfe486a7c42f)

## About the filer

- CIK: 1801170
- Tickers: CLOV
- Exchange: Nasdaq
- SIC code: 6324 Hospital & Medical Service Plans
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.